(Q37842962)

24 August 2017

1 reference

title

Monoclonal antibodies for medical oncology: a few critical perspectives (English)

1 reference

24 August 2017

1 reference

1 reference

Cristóbal Belda-Iniesta

series ordinal

1

1 reference

PubMed ID

21324795

24 August 2017

Inmaculada Ibáñez de Cáceres

series ordinal

2

1 reference

PubMed ID

21324795

24 August 2017

Javier de Castro

series ordinal

3

1 reference

24 August 2017

1 February 2011

1 reference

Clinical and Translational Oncology

24 August 2017

1 reference

24 August 2017

13

1 reference

24 August 2017

2

1 reference

24 August 2017

84-87

1 reference

https://scigraph.springernature.com/pub.10.1007/s12094-011-0623-z

24 August 2017

0 references

cites work

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0623-Z

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0623-Z

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0623-Z

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0623-Z

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0623-Z

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0623-Z

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0623-Z

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0623-Z

Panitumumab: a review of its use in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0623-Z

Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0623-Z

Chemotherapy for advanced gastric cancer

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21324795

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

HER2 and hormone receptor-positive breast cancer--blocking the right target

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21324795

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12094-011-0623-Z

1 reference

24 August 2017

1 reference

PubMed ID

21324795